Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2013 May 10;31(14):1713-8.
doi: 10.1200/JCO.2012.44.1238. Epub 2013 Mar 25.

Elevated Risk of Prostate Cancer Among Men With Lynch Syndrome

Affiliations
Free PMC article
Comparative Study

Elevated Risk of Prostate Cancer Among Men With Lynch Syndrome

Victoria M Raymond et al. J Clin Oncol. .
Free PMC article

Abstract

Purpose: Prostate cancer has been described as a component tumor of Lynch syndrome (LS), with tumors obtained from mutation carriers demonstrating the DNA mismatch repair deficiency phenotype. Previous studies quantifying prostate cancer risk in LS have provided conflicting results.

Methods: We examined cancer histories of probands and their first- through fourth-degree relatives for 198 independent mutation-positive LS families enrolled in two US familial cancer registries. Modified segregation analysis was used to calculate age-specific cumulative risk or penetrance estimates, with accompanying Wald-type CIs. Cumulative lifetime risks and hazard ratio (HR) estimates for prostate cancer were calculated and compared with those of the general population.

Results: Ninety-seven cases of prostate cancer were observed in 4,127 men. Median age at prostate cancer diagnosis was 65 years (range, 38 to 89 years), with 11.53% of affected individuals diagnosed before age 50 years. The cumulative risk of prostate cancer at ages 60 and 80 years was 6.30% (95% CI, 2.47 to 9.96) and 30.0% (95% CI, 16.54 to 41.30), as compared with the population risk of 2.59% and 17.84%, respectively. The overall prostate cancer HR among carriers was 1.99 (95% CI, 1.31 to 3.03).

Conclusion: The cumulative lifetime risk of prostate cancer in individuals with LS is two-fold higher than in the general population and is slightly higher in carriers diagnosed before age 60 years (HR, 2.48; 95% CI, 1.34 to 4.59). These estimates are clinically valuable to quantify risk for both patients and providers.

Conflict of interest statement

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Figures

Fig 1.
Fig 1.
Cumulative risk of prostate cancer in mismatch repair gene mutation carriers compared with general population rates reported in SEER 13; 95% Wald-type CIs are included at ages 60 and 80 years. DFCI, Dana-Farber Cancer Institute; UMCC, University of Michigan Comprehensive Cancer Center.

Comment in

Similar articles

See all similar articles

Cited by 41 articles

See all "Cited by" articles

Publication types

Feedback